Printer Friendly

CEPHALON FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR THE USE OF MYOTROPHIN FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

 CEPHALON FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR THE USE
 OF MYOTROPHIN FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
 WEST CHESTER, Pa., June 30 /PRNewswire/ -- Cephalon, Inc. (NASDAQ: CEPH) today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for the use of Myotrophin(TM) for the treatment of amyotrophic lateral sclerosis (ALS).
 ALS, also known as Lou Gehrig's disease, is a fatal disorder of the nervous system characterized by the chronic, progressive degeneration of motor neurons. Death typically occurs three to five years after onset of the disease, as a result of respiratory failure. ALS afflicts approximately 25,000 people in the United States.
 In April, the company initiated human clinical trials of Myotrophin in the United Kingdom under protocols designed to conform to the U.S. FDA guidelines for Phase I trials. A total of 48 individuals participated in the trial. The data from this trial was included in the company's IND filing, under which the company is seeking to begin clinical trials in ALS patients.
 "Today's IND filing is consistent with the projected development plan for Myotrophin that the company has been pursuing over the last two years," indicated Frank Baldino Jr., president and CEO of Cephalon, Inc. "We are anxious to begin clinical studies in patients with this horribly debilitating disease."
 Cephalon, Inc. focuses on the development of products to treat neurodegenerative diseases. These diseases are characterized by the death of neurons, the specialized conducting cells of the nervous system. The company has concentrated its research programs on the prevention of neuronal death in several disorders, including ALS, Alzheimer's disease, head and spinal cord injuries, stroke, peripheral neuropathy and retinopathy. There is currently no effective treatment for these conditions which, in the aggregate, afflict over six million people in the U.S. Cephalon has identified potential therapeutic compounds for each of these disorders.
 -0- 6/30/92
 /CONTACT: Nicole Vitullo of Cephalon, 215-344-0200, or Karen Bergman of Burns McClellan, 212-545-1919, for Cephalon/
 (CEPH) CO: Cephalon, Inc. ST: Pennsylvania IN: MTC SU:


SH-OS -- NY062 -- 5207 06/30/92 13:22 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1992
Words:353
Previous Article:LESSONWARE COMPLETES INITIAL PUBLIC OFFERING
Next Article:WETTERAU UNABLE TO REACH AGREEMENT WITH SUPERVALU INC.
Topics:


Related Articles
CEPHALON NAMES VICE PRESIDENT OF DRUG DEVELOPMENT
CEPHALON, INC.'S MYOTROPHIN(TM) DEMONSTRATES SAFETY IN PHASE I TRIALS
CEPHALON BEGINS MYOTROPHIN CLINICAL TRIALS IN JAPAN
CEPHALON RECEIVES SECOND MYOTROPHIN USE PATENT
CEPHALON SUBMITS TREATMENT IND FOR MYOTROPHIN TO FDA
MYOTROPHIN SCHEDULED FOR JUNE FDA ADVISORY PANEL MEETING
FDA CLEARS MYOTROPHIN EARLY ACCESS PROGRAM FOR PATIENTS WITH ALS
MYOTROPHIN EXPANDED ACCESS PROGRAM LAUNCHED FOR PATIENTS WITH ALS
Cephalon Exercises Option to Broaden License to SIBIA'S IGF-1 Production Technology to Include Non-Neurological Applications
Cephalon and Chiron Submit New Drug Application For Myotrophin to Food and Drug Administration

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters